Home・Lista de Ações・Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

Fechado

1.83 2.81

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.72

Máximo

1.83

Indicadores-chave
By Trading Economics
Rendimento	-23T -3.5M
EPS	-0.06
Funcionários	7
EBITDA	3M -2.9M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+9.29% upside

Dividendos
By Acuity
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	26M 124M
Abertura anterior	-0.98
Fecho anterior	1.83

Aldeyra Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de jun. de 2026, 23:51 UTC

"Bitcoin rises as Ethereum falls amid pivotal AI earnings reports, while U.S. credit rating remains stable and China's industrial profits soar."

27 de jun. de 2026, 23:51 UTC

China's industrial profits rise 18.8% amid AI investments; U.S. credit rating affirmed at AA+ as markets brace for modest growth and pivotal Meta earnings report.

27 de jun. de 2026, 23:51 UTC

Cryptocurrency market shows mixed signals as investors brace for key AI earnings reports and upcoming economic indicators amid cautious U.S. growth outlook.

27 de jun. de 2026, 23:51 UTC

Mixed cryptocurrency performance reflects cautious investor sentiment ahead of key economic indicators and AI earnings reports, while U.S. credit rating remains stable amid inflation concerns.

27 de jun. de 2026, 23:51 UTC

Bitcoin is trading higher since Friday's close, remaining flat during the current session. The price fluctuated within a routine range today.

27 de jun. de 2026, 23:42 UTC

U.S. Labor Force Participation Rate Release on July 2, 2026: Market Cautious Amid Declining Employee Confidence and Legislative Changes Impacting Employment Dynamics.

27 de jun. de 2026, 23:42 UTC

Market Awaits BoC Governor Macklem's Speech on Interest Rate Policy Amid Economic Uncertainties

27 de jun. de 2026, 23:42 UTC

Market Eyes BoE Governor Bailey's July Speech for Insights on UK Interest Rates Amid Global Monetary Policy Shifts.

27 de jun. de 2026, 23:42 UTC

Market Anticipates 0.3% Increase in U.S. Average Hourly Earnings Amid Wage Growth Concerns and Inflation Pressures Ahead of July Release.

27 de jun. de 2026, 23:42 UTC

U.S. Unemployment Rate Release on July 2, 2026 Expected at 4.3%, Amid Concerns Over Employee Confidence and Potential Minimum Wage Legislation Impacting Markets

27 de jun. de 2026, 23:42 UTC

Market Anticipates 114K Job Additions in Upcoming June NFP Report Amid Mixed Economic Sentiment and Inflation Concerns.

27 de jun. de 2026, 23:42 UTC

Market Awaits Key Average Hourly Earnings Data Amidst Rising Inflation Concerns and Potential Federal Reserve Rate Implications on July 2, 2026.

27 de jun. de 2026, 23:31 UTC

Mexican Consumer Confidence Expected to Remain Low Amid Economic Challenges Ahead of July 3 Data Release.

27 de jun. de 2026, 23:11 UTC

ADP Employment Change Report Forecasts 118,000 Job Increase Amid Cautious Optimism in Labor Market Ahead of July Release.

27 de jun. de 2026, 23:11 UTC

Correlated Moves

S&P 500 Index declines in after-market trading, reflecting cautious sentiment ahead of upcoming earnings reports from AI-linked companies like Meta.

27 de jun. de 2026, 23:11 UTC

Correlated Moves

The Russell 2000 Index is lower in after-market trading, reflecting broader market sentiment amid upcoming earnings reports from AI-linked companies.

27 de jun. de 2026, 23:11 UTC

Correlated Moves

The Dow Jones Index is lower in after-market hours, reflecting unusual trading activity and broader declines seen in the Russell 2000 Index.

27 de jun. de 2026, 23:11 UTC

The FTSE 100 Index is lower in after-market hours, reflecting a dip since Friday's close. Anticipation of corporate earnings reports may influence market sentiment.

27 de jun. de 2026, 23:11 UTC

Correlated Moves

The Nasdaq 100 Index is lower during after-market hours, continuing a downward trend since Friday's close amid broader market weakness and upcoming earnings anticipation.

27 de jun. de 2026, 23:02 UTC

Canada's May GDP report set for June 30, with a projected growth of 0.4% amid mixed stock performance and trade uncertainties.

27 de jun. de 2026, 22:32 UTC

Germany's June 30 inflation rate forecasted to rise by 0.1%, raising concerns over persistent inflation and potential ECB monetary policy shifts amid global economic pressures.

27 de jun. de 2026, 22:32 UTC

Germany's June 2026 Inflation Rate Release Expected at 2.5% Amid Rising Global Price Pressures and Cautious Market Sentiment

27 de jun. de 2026, 22:32 UTC

Japan's Tankan Large Manufacturers Index set for June 30, with cautious market sentiment amid stock declines and mixed economic signals.

27 de jun. de 2026, 22:32 UTC

South Africa's Upcoming Balance of Trade Data Expected to Show Significant Shift Amid Rising Imports and Mixed Export Performance

27 de jun. de 2026, 22:21 UTC

Brazil's Central Bank to Provide Key Insights on Interest Rate Outlook Amid Rising Global Pressures in June 29 Readout.

27 de jun. de 2026, 22:11 UTC

Japan's Industrial Production Expected to Rise 1.1% in May Amid Mixed Market Sentiment and Economic Concerns

27 de jun. de 2026, 22:02 UTC

South Korea's June 2026 Inflation Rate Release Sparks Market Caution Amid Rising Price Pressures and Regional Economic Concerns.

27 de jun. de 2026, 21:51 UTC

Japan's Retail Sales YoY data for May set to release on June 28, with a projected growth of 3.2% amid mixed market sentiment and inflation concerns.

27 de jun. de 2026, 21:51 UTC

Japan's Unemployment Rate Expected to Stabilize at 2.5% Amid Mixed Economic Sentiment and Market Volatility

27 de jun. de 2026, 21:41 UTC

Cautious Sentiment Surrounds Upcoming Ai Group Industry Index Release Amid Ongoing Economic Challenges in Australia

Comparação entre Pares

Variação de preço

Aldeyra Therapeutics Inc Previsão

Preço-alvo

By TipRanks

9.29% parte superior

Previsão para 12 meses

Média 2 USD 9.29%

Máximo 2 USD

Mínimo 2 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Aldeyra Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Aldeyra Therapeutics Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.